MedTrace Logo

Neurofeedback to Treat Depression - 2

NCT07159061 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-12-04

No results posted yet for this study

Summary

This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

BEHAVIORAL

Active Closed Loop Real Time fMRI Neurofeedback

Active neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)

BEHAVIORAL

Sham Closed Loop Real Time fMRI Neurofeedback

Sham (placebo) neurofeedback to target neural mechanisms underlying attentional bias in participants with major depressive discover (MDD)

Sponsors & Collaborators

Principal Investigators

  • Yvette Sheline, M.D. · Center for Neuromodulation in Depression and Stress, University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-21
Primary Completion
2028-11-21
Completion
2028-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07159061 on ClinicalTrials.gov